Lotus Tissue Repair secures $26M series A funds
This article was originally published in Scrip
Executive Summary
Lotus Tissue Repair, founded in 2011 to focus on wound healing indications, has raised $26 million in a series A round led by Third Rock Ventures. Proceeds of the round will be used to advance the development of recombinant collagen type VII (rc7) technology which the company has licensed exclusively from the University of Southern California laboratory of scientific co-founders Dr Mei Chen and Dr David Woodley.